Cipla Q4 Results Miss Estimates, Neutral Rating Maintained

Overview

Goldman Sachs publishes commentary on Indian pharmaceutical company Cipla's FY2026 Q4 results. The report notes Cipla's Q4 performance fell short of expectations with revenue declining 3% YoY, primarily due to the gRevlimid patent cliff in the US, Lanreotide supply constraints, and slower pipeline commercialization. Despite overall pressure, its core Indian market and Africa (One Africa) operations demonstrated strong growth momentum. Given balanced risk-reward, Goldman maintains a 'Neutral' rating on Cipla but slightly raises the 12-month target price to Rs1,350 based on updated earnings forecasts.

Core views

India & Africa as growth engines: India operations achieved ~15% YoY growth in Q4 with all three segments delivering double-digit growth. Prescription business performed exceptionally well in respiratory, diabetes, cardiac, and urology segments, with significant contributions from four licensed brands through Pfizer partnership. Management remains confident about outperforming the Indian Pharmaceutical Market (IPM) in FY27, expecting no recurrence of seasonal slowdowns in acute branded prescription business. Meanwhile, One Africa grew 14% YoY with private market up 20% and South Africa tender business achieving over 50% strong growth in Q4. US faces near-term headwinds: US Q4 revenue stood at $155 million, down ~7% QoQ and 30% YoY, mainly due to significant gRevlimid revenue decline and Lanreotide supply constraints since December 2025 due to quality inspection requirements. While Albuterol maintains stable market share (20%), the company anticipates share gains post gVentolin launch in FY27 Q1. For Lanreotide, Cipla is working with partners on remediation, expecting FDA reinspection timeline clarity next quarter, and has identified alternative suppliers with plans to submit applications early next calendar year for potential FY28 relaunch. Earnings guidance cut & valuation adjustments: Due to lower gRevlimid contributions, Lanreotide headwinds, and increased R&D spend (now ~7% of sales), the company lowered FY27 EBITDA margin guidance to 18.5%-20% (100-250bps below FY26). Goldman accordingly adjusted FY27-29 EPS forecasts (-2% to +4% changes) and raised the SOTP-based 12-month target price from Rs1,325 to Rs1,350, implying ~22x P/E.

Analysis framework

Goldman employed a Sum-of-the-Parts (SOTP) analysis to evaluate Cipla's value, examining its India, US, and Africa operations separately. This approach helps identify growth drivers and risks across markets, such as India's organic growth versus US patent cliff impacts. Valuation-wise, forward P/E multiples served as the primary anchor combined with EPS forecasts to determine target price. The report also referenced historical valuation averages (e.g., 5-year average P/E) to assess relative attractiveness.

Methodology notes

• Valuation MethodSOTP Valuation

  SOTP Valuation

  Valuing different business segments (e.g., India, US, Africa) separately before aggregation, suitable for diversified multinationals with distinct growth logics across segments, providing more precise valuation.

• Valuation MethodPE/PEG valuation

  PE/PEG Valuation

  Using P/E as the primary valuation metric combined with earnings growth expectations. The report notes current P/E trades below 5-year average as a reference for valuation rationality.

• Industry Analysis Framework

  Patent Cliff & Pipeline Analysis

  In generics, patent expirations (cliffs) cause revenue cliffs while new product approvals (pipeline commercialization) are key to filling gaps. Analysts closely track gRevlimid decline and gVentolin/Lanreotide progress.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Cipla (CIPL.BO)

  Coverage Target

  Strengths

  Strong growth in India & South Africa, robust pipeline, stable cash flows

  Weaknesses

  US patent cliff & supply chain challenges, near-term margin pressure

  Risks

  Intensified US competition, key product approval delays, currency volatility

Key data

• Q4 FY26 RevenueRs65.412 billionDown 3% YoY, 8% QoQ, below GS estimates
• Q4 FY26 EBITDA Margin14.6%Down 825bps YoY, in line with estimates
• India Business Q4 Growth~15%Strong YoY growth with all segments double-digit
• US Business Q4 Revenue$155 millionDown ~7% QoQ, 30% YoY
• FY27 EBITDA Margin Guidance18.5% - 20%100-250bps below FY26
• 12-month Target PriceRs1,350Raised from Rs1,325, implying ~22x P/E

Impact & implications

The report suggests that while near-term performance is impacted by US-specific product issues, Cipla's fundamentals in core markets like India and South Africa remain solid with potential to outperform. US business targets $1 billion annualized revenue run-rate by FY27-end, contingent on successful high-value product launches. Lowered margin guidance reflects product mix changes and increased R&D investments - investors should monitor execution on new launches and regulatory approvals.

Risks

• US pricing erosion from intense competition
• Faster/slower-than-expected Lanreotide ramp-up
• Pipeline commercialization delays
• Uncertainty in key respiratory product approvals
• Subpar US execution

What to watch

• FY27 US $1 billion annualized revenue run-rate achievement
• Lanreotide FDA reinspection timeline & remediation progress
• gVentolin launch and sales traction in FY27
• India domestic business's ability to sustain market outperformance in FY27